

one time data collection questionnaire. Each CBO will be asked to answer questions related to the existence and importance of factors affecting their HIV prevention interventions. This data collection is necessary for CDC to better (a) assess CBO applications systematically for funding, (b) develop materials CBOs can use to assess their own programmatic needs and create a social map of their target populations,

including a CBO profile of organizational, environmental, target population, intervention program and accomplishments characteristics, (c) better develop CBO technical assistance (TA) materials, and (d) provide TA to CBOs that have already been selected by CDC for funding. This study will also yield more hypotheses for statistical testing, instruments with reliability and validity data for use in other studies,

and a model that can be used and revised to meet the context of a particular CBO. The questionnaire will be administered to 766 CBOs that have applied for CDC funding under program announcements 00023, 00100, 99047, 99091, 99092, 99096. The total response burden for this data collection is 1532 hours.

Respondents	Number of respondents	Number of responses per respondent	Avg. burden per response (in hrs.)
Model Survey	766	1	2

Dated: July 12, 2001.

Nancy Cheal,

Acting Associate Director for Policy, Planning, and Evaluation Centers for Disease Control and Prevention (CDC).

[FR Doc. 01-18353 Filed 7-23-01; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY-43-01]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). To request a copy of these

requests, call the CDC Reports Clearance Officer at (404) 639-7090. Send written comments to CDC, Desk Officer; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503. Written comments should be received within 30 days of this notice.

Proposed Project

Assessing the Effectiveness of Community-Based Organizations (CBOs) for the Delivery of HIV Prevention Intervention: Process Evaluation—New—Centers for Disease Control and Prevention (CDC), National Center for HIV, STD, and TB Prevention (NCHSTP) proposes to evaluate HIV prevention programs in community-based organizations (CBOs) through a quarterly and annual reporting system. This evaluation is necessary to understand the impact of CDC's expenditures and efforts to support CBOs, and for modifying and improving the prevention efforts of CBOs. This

data collection will provide CDC with standardized data which will allow CDC to (a) determine the extent to which HIV prevention efforts have contributed to a reduction in HIV transmission nationally; (b) improve programs to better meet the goal of reducing HIV transmission; (c) help focus technical assistance and support; and (d) be accountable to stakeholders by informing them of progress made in HIV prevention nationwide. CDC currently funds 181 CBOs.

Each CBO will be asked to report on the following types of interventions that it has implemented (a) individual level interventions; (b) group level interventions; (c) street and community outreach; (d) prevention case management; (e) partner counseling and referral services; (f) health communications/public information; (g) community level interventions; and (h) HIV antibody counseling and testing.

The total response burden for this data collection is 1,810 hours.

Respondents	Number of respondents	Number of responses	Avg. burden per response (in hrs.)
Intervention Plan	181	1	2
Process Monitoring	181	4	2

Dated: July 12, 2001.

Nancy Cheal,

Acting Associate Director for Policy, Planning, and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 01-18354 Filed 7-23-01; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Draft Research Agenda for the National Center for Injury Prevention and Control

AGENCY: Centers for Disease Control and Prevention, Department of Health and Human Services.

ACTION: Notice of the availability of draft research agenda and request for comments.

SUMMARY: The Centers for Disease Control and Prevention (CDC) announces the availability of the Draft Research Agenda for the National Center for Injury Prevention and Control (NCIPC) and solicits comments during the public comment period of July 18, 2001, through August 20, 2001. Over the past year, NCIPC has been developing a research agenda based on input from internal staff and external experts in the

field of injury prevention and control. The research themes presented are designed to represent the breadth and depth of the field within eight topic areas including; suicide, youth violence, intimate partner violence/sexual violence/child maltreatment, transportation and mobility, sports/recreation/exercise, residential and community safety, acute care, and disability and rehabilitation.

DATES: Public comment period will be July 18–August 20, 2001.

ADDRESSES: Interested persons are invited to comment on the Draft Research Agenda. NCIPC will not be able to respond to individual comments, but all comments received by August 20, 2001, will be considered before the final Research Agenda is published. View the Draft Research Agenda and submit comments electronically at <http://www.qrc.com/ncipcagenda>.

Alternatively, hard copy versions of the draft research agenda may be obtained by contacting Dr. Judy Berkowitz at ORC Macro, 3 Corporate Square, NE., Suite 370, Atlanta, GA 30329. Telephone 404–321–3211 or Email address: agenda@macroint.com.

FOR FURTHER INFORMATION CONTACT: Dr. Judy Berkowitz, ORC Macro 3 Corporate Square, NE., Suite 370, Atlanta, GA 30329. Email address: agenda@macroint.com. Telephone: (404) 321–3211.

Dated: July 18, 2001.

Joseph R. Carter,

Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 01–18371 Filed 7–23–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Call for Public Comments on 16 Substances, Mixtures and Exposure Circumstances Proposed for Listing in the Report on Carcinogens, Eleventh Edition

Background

The National Toxicology Program (NTP) announces its intent to review additional agents, substances, mixtures and exposure circumstances for possible listing in the Report on Carcinogens (RoC), Eleventh Edition that is scheduled for publication in 2004. This Report (previously known as the Annual Report on Carcinogens) is a Congressionally mandated listing of known human carcinogens and

reasonably anticipated human carcinogens and its preparation is delegated to the National Toxicology Program by the Secretary, Department of Health and Human Services (DHHS). Section 301(b)(4) of the Public Health Service Act, as amended, provides that the Secretary, DHHS shall publish a report, which contains a list of all substances (1) which either are known to be human carcinogens or may reasonably be anticipated to be human carcinogens, and (2) to which a significant number of persons residing in the United States (US) are exposed. The law also states that the reports should provide available information on the nature of exposures, the estimated number of persons exposed and the extent to which the implementation of Federal regulations decreases the risk to public health from exposure to these chemicals.

The scientific review of the nominated agents, substances, mixtures or exposure circumstances involves three separate scientific reviews: Two Federal review groups and one non-government peer review body (a subcommittee of the NTP Board of Scientific Counselors) that meets in an open, public forum. Throughout the review process, multiple opportunities are provided for public input including comment at the public meeting of the NTP Board Subcommittee. In reviewing nominations for the RoC, all available data and public comments are considered in the application of the criteria for inclusion or removal of candidate agents, substances, mixtures or exposure circumstances or for a change in a candidate's classification. The criteria used in the review process are as follows:

Known To Be Human Carcinogens

There is sufficient evidence of carcinogenicity from studies in humans which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer.

Reasonably Anticipated To Be Human Carcinogens

There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or

There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) In multiple species, or at multiple tissue

sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or at onset; or

There is less than sufficient evidence of carcinogenicity in humans or laboratory animals; However, the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.

Conclusions regarding carcinogenicity in humans or experimental animals are based on scientific judgment, with consideration given to all relevant information. Relevant information includes, but is not limited to dose response, route of exposure, chemical structure, metabolism, pharmacokinetics, sensitive sub populations, genetic effects, or other data relating to mechanism of action or factors that may be unique to a given substance. For example, there may be substances for which there is evidence of carcinogenicity in laboratory animals but there are compelling data indicating that the agent acts through mechanisms which do not operate in humans and would therefore not reasonably be anticipated to cause cancer in humans.

A detailed description of the review procedures, including the steps in the formal review process, is available at <http://ntp-server.niehs.nih.gov> or can be obtained by contacting: Dr. C.W. Jameson, National Toxicology Program, Report on Carcinogens, 79 Alexander Drive, Building 4401, Room 3118, P.O. Box 12233, Research Triangle Park, NC 27709; phone: (919) 541–4096, fax: (919) 541–0144, email: jameson@niehs.nih.gov.

Public Comment Requested

The following table identifies the 16 nominations the NTP may consider for review in 2001 or 2002, as either a new listing in or changing the current listing from reasonably anticipated to be a human carcinogen to the known to be a human carcinogen category in the Eleventh Report. These nominations are provided with their Chemical Abstracts Services (CAS) Registry numbers (where available) and pending review action. Additional nominations for the Eleventh Report or modifications to the nominations in the attached table may be identified and would be announced in future **Federal Register** notices. The NTP solicits public input on these 16 nominations and asks for relevant